Generics Catch A Break With Hikma's Skinny Label Win
Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off...To view the full article, register now.
Already a subscriber? Click here to view full article